Talk:Clazakizumab
 | This article was nominated for deletion on 11 November 2009 (UTC). The result of the discussion was keep. |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Clazakizumab.
|
cachexia and recent trials
editcachexia links here. Also need updates on the trials that were due to report in 2010. - Rod57 (talk) 13:08, 2 November 2011 (UTC)
Crohns disease
editPhase II trial for Crohns disease to run until 2015 also implies that Alder retain the ALD518 name for cancer applications. - Rod57 (talk) 23:08, 3 September 2012 (UTC)
should move BMS-945429 to clazakizumab
editRe name: See Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis .... - Rod57 (talk) 15:12, 24 September 2015 (UTC)
To preserve history here I guess we should bring content from clazakizumab here then rename back ? - Rod57 (talk) 12:13, 20 December 2015 (UTC)
- done the merge - now try to rename back - Rod57 (talk) 14:51, 20 December 2015 (UTC)
Requested move 20 December 2015
edit {{requested move/dated|Clazakizumab}}
BMS-945429 → Clazakizumab – mAB now has name but there was already a stub - which has now been merged into this. Rod57 (talk) 15:00, 20 December 2015 (UTC)
- Now realise I should have just made a 'technical move request' or asked for the target page to be deleted. (I've made the tech-move-request and commented out the request above ) - Rod57 (talk) 02:16, 21 December 2015 (UTC)
Need to clarify Mechanism of action esp re cancer
editMay only be intended to treat cachexia/weight-loss/fatigue effects of cancer rather than affect the tumour growth directly ? - Rod57 (talk) 17:47, 21 December 2015 (UTC)